Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

This study has been completed.
Information provided by:
Hoffmann-La Roche Identifier:
First received: November 12, 2002
Last updated: August 11, 2005
Last verified: August 2005
The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.

Condition Intervention Phase
Chronic Hepatitis B
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of hepatitis B
  • Not pregnant

Exclusion Criteria:

  • Treatment for hepatitis B in past 6 months
  • Other hepatitis infections
  • Severe liver disease
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00048945

  Show 74 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
  More Information Identifier: NCT00048945     History of Changes
Other Study ID Numbers: WV16240 
Study First Received: November 12, 2002
Last Updated: August 11, 2005
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hepatitis, Chronic
Hepatitis B
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Hepatitis, Viral, Human
Peginterferon alfa-2a
Antiviral Agents
Anti-Infective Agents processed this record on December 02, 2016